

System	Indication	Phase	R*	Specification	No. of centres**	No. of patients**	Countries involved***	****
CARD	Cardiac dysrhythmia	IV			08	100	CR, (G)	C
CARD	Heart failure	IV			05	60	CR, (G)	C
CARD	MI acute, fibrinolysis	III	R	18 PCI sites	90	ET [LoE]	CR, HU (WW)	C
ENDO	Acromegaly	III	R		02	20	CR, (EU)	C
ENDO	Acromegaly	III	R	Macroadenoma	03	20	CR, (EU)	↔
ENDO	Small gestation age	IV		limited to site set-up	11	00	CR, SK, (EU)	C
GAST	Colitis ulcerosa	III			10	60	CR, SK, (G)	C
GYN	In-vitro Fertilisation	Ila	R	donor stimulation	01	20	CR (EU)	C
GYN	In-vitro Fertilisation	II	R	uterine contractions	02	35	CR, (EU)	C
GYN	In-vitro Fertilisation	II	R	uterine contractions	02	30	CR, (EU)	↔
GYN	Hormonal Replacement 1	III	R	prior to guideline	20	200	CR, (G)	C
GYN	Hormonal Replacement 2	III	R	CPMP/EWP/021/97	20	150	CR, (G)	C
GYN	Hormonal Replacement 3	III	R	CPMP/EWP/021/97	15	150	CR, (G)	C
GYN	Hormonal Replacement 4	III	R	CPMP/EWP/021/97	20	160	CR, (G)	C
GYN	Hormonal Replacement 5	IV	R	CPMP/EWP/021/97	40	280	CR, PL, (G)	C
GYN	Hormonal Replacement 6	IV	R	CPMP/EWP/021/97	45	400	CR, PL	C
GYN	Mastalgia	III	R	phyto-pharm. IMP	01	100	CR	C
GYN	Mastalgia/ PMS	IV	R	phyto-pharm. IMP	08	180	CR	↔
GYN	Osteoporosis treatment	III			01	50	SK, (G)	C
GYN	Postmenopausal syndrome	III	R	phyto-pharm. IMP	20	160	CR	C
GYN	Premenstrual syndrome	III	R	phyto-pharm. IMP	20	300	CR	C
INT	Anemia	III		pre-dialysis patients	15	80	CR, SK (EU)	C
INT	Diabetes mellitus type II	II	R	first long-term appl.	05	20	CR (EU)	C
INT	Hypertension	IV		renal transplant pat.	01	50	CR (EU)	C
NEUR	Dementia 1	III		DAT	08	120	CR, SK (EU)	C
NEUR	Dementia 2	III	R	DAT and MID	08	140	CR, SK (EU)	C
NEUR	Dementia 3	III	R	DAT and MID	10	140	CR, SK (EU)	C
NEUR	Mild Cognitive Impairment	III		phyto-pharm. IMP	25	ET [Str]	CR, SK	C
NEUR	Depression	III	R	«pain enriched»	10	100	CR, SK (EU)	C
NEUR	Multiple Sclerosis 1	IV		data auditing PASS	10	200	CR	C
NEUR	Multiple Sclerosis 2	Iib	R	MRI-controlled	06	ET [Saf]	CR, (WW)	C
ONCO	Renal Cell Carcinoma	II		vaccination	04	ET [Str]	CR, A	C
OPHTH	Conjunctivitis	III			05	100	CR	C
PULM	Anti-infective therapy	IV		pneumonia	09	90	CR, HU (EU)	C
PULM	Bronchitis	PAS		children	02	100	G	C
PULM	COPD	IV		COPD subgroup	80	500	CR, PL, HU (G)	C
PULM	Influenza	III		Phyto IMPvs Tamiflu	25	500	CR	P
RHEU	Osteoarthritis	PAS		knee/ hip	240	1.700	CR	C
SEX	Premature ejaculation	III			05	30	CR, PL	C
SURG	Anti-infective prophylaxis	III		elective surgery	01	20	CR, (EU)	C
UROL	Prostate cancer 1	III	R		05	35	CR, (G)	C
UROL	Prostate cancer 2	III	R		20	90	CR, PL, (EU)	C
UROL	Urinary incontinence 1	IV		long-term 1 y	15	190	CR, SK, (EU)	C
UROL	Urinary incontinence 2	IV	R		10	100	CR	C
UROL	Urinary incontinence 3	III	R	long-term 1 y	10	100	CR, (EU)	C
UROL	Urinary incontinence 4	III	R		15	140	CR, SK, (EU)	C
UROL	Urinary incontinence 5	I	R	monitoring, auditing	01	06	CR	C
UROL	Urinary incontinence 6	III	R		06	60	CR, (EU)	C
UROL	Urinary incontinence 7	III	R	children	05	30	CR, SK, (EU)	C

* Repeat business (more than one trial by the same sponsor), overall repeat ratio about 60%

** Share in CEE- countries managed by PHAMOS

ET= early terminated due to lack of efficacy LoE, Safety Saf or by sponsor's strategic decision Str

*** Countries managed by PHAMOS, in brackets other countries not managed by PHAMOS but by sponsor or other CROs (EU stands for more than one other EU country, WW for global studies)

**** Status as of AUG 2010: Completed, in Preparation, ↔ ongoing

Sponsors we have been working for:

AOP Orphan, Apogepha, Bionorica, Bioforce, Boehringer Ingelheim, Dentinox, Falk Pharma, Ferring, Hexal Biotech, Ipsen, Jenapharm, Lilly, Madaus, Merckle, Novartis, NovoNordisk, Parke Davis, Plantamed, Plethora Solutions, Sandoz, Schering, Schwabe, Serono, S&K Pharma, Slovakopharma, SKB, Takeda, Trimed Biotech, Wyeth, Yamanouchi